



STERLING BIOTECH LIMITED

CIN No. L51900MH1985PLC035738

Regd. Office. : 43 Atlanta Building, Nariman Point, Mumbai-400 021.
Tel. : +91(22) 6630 6732, 6630 6733 * Fax : +91 (22) 2204 1954

30 May 2016

To
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Dear Sir,

Sub.: Approval of Annual Audited Results for the financial year of 15 months ended on 31 March 2016.

The Board of Directors of the Company today at their meeting considered, approved and adopted Annual Audited Results for the Financial Year of 15 months ended 31 March, 2016, in compliance of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board of Directors has not recommended any dividend for the financial year of 15 months ended 31 March 2016.

Please find enclosed herewith the Audited Results in the prescribed format as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as considered and approved by the Board for your kind perusal and record. We also enclose herewith the Auditors Report on the said Annual Audited Financial Results and Form B.

The Annual results will be published in the news papers as required in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We kindly request you to take the same on record.

Thanking you,
Yours Faithfully,

For Sterling Biotech Limited


Chetan Sandesara
Joint Managing Director
DIN: 00255671



CC to :

National Stock Exchange of India Ltd.
"EXCHANGE PLAZA", Bandra Kurla
Complex, Bandra (E), Mumbai 51

Luxembourg Stock Exchange,
Luxembourg

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021
CIN - L51900MH1985PLC035738

AUDITED FINANCIAL RESULTS FOR THE YEAR OF 15 MONTHS ENDED 31 MARCH 2016

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Fifteen Months ended	Twelve Months ended
		31/03/2016	31/12/2015	31/03/2015	31/03/2016	31/12/2014
		Audited (Refer Note No. 5)	Unaudited	Unaudited	Audited	Audited
1	Income from Operations					
a)	Net Sales/Income from Operations	11,312.08	8,630.94	10,062.99	52,399.02	66,695.07
b)	Other Operating Income	307.81	117.00	142.53	784.95	368.20
c)	Total Income from Operations	11,619.89	8,747.94	10,205.52	53,183.97	67,063.27
2	Expenses					
a)	Cost of materials consumed	6,198.26	6,578.84	17,329.82	44,437.31	61,783.87
b)	Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,551.78	(572.71)	(10,548.63)	(8,993.27)	(15,232.62)
d)	Employee benefits expense	1,377.49	1,359.76	1,226.99	6,610.86	5,167.27
e)	Depreciation and amortization expense	7,023.04	7,021.73	7,049.55	35,132.04	27,657.43
f)	Other Expenses	775.14	807.91	881.99	3,899.30	3,852.80
g)	Total Expenses	16,925.71	15,195.53	15,939.72	81,086.24	83,228.75
3	Profit / (Loss) from Operations before Other Income and finance Costs (1-2)	(5,305.82)	(6,447.59)	(5,734.20)	(27,902.27)	(16,165.48)
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from Ordinary activities before finance costs (3+4)	(5,305.82)	(6,447.59)	(5,734.20)	(27,902.27)	(16,165.48)
6	Finance Costs	8,289.82	8,920.00	7,639.36	41,478.19	46,950.57
7	Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)	(13,595.64)	(15,367.59)	(13,373.56)	(69,380.46)	(63,116.05)
8	Tax expense					
a)	Current	0.00	0.00	0.00	0.00	0.00
b)	Deferred	(4,411.00)	(4,986.00)	(4,339.00)	(22,511.00)	(20,478.00)
c)	Total	(4,411.00)	(4,986.00)	(4,339.00)	(22,511.00)	(20,478.00)
9	Net Profit / (Loss) from Ordinary Activities after tax (7-8)	(9,184.64)	(10,381.59)	(9,034.56)	(46,869.46)	(42,638.05)
10	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
11	Net Profit / (Loss) for the period (9+10)	(9,184.64)	(10,381.59)	(9,034.56)	(46,869.46)	(42,638.05)
12	Prior year adjustment	0.00	0.00	0.00	0.00	(3,132.47)
13	Profit available for appropriation	(9,184.64)	(10,381.59)	(9,034.56)	(46,869.46)	(45,770.52)
14	Paid-up equity share capital (Face Value of Re. 1/- per share)	2,721.70	2,720.48	2,720.48	2,721.70	2,720.48
15	Paid-up Debt Capital #	N.A.	N.A.	N.A.	133,383.52	127,445.14
16	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				54,228.78	101,026.03
17	Debenture Redemption Reserve	N.A.	N.A.	N.A.	4,982.14	4,982.14
18.i	Earnings Per Equity Share (EPS) (before extraordinary items) (F.V. of Re. 1/- each) (not annualised)					
a)	Basic	(3.37)	(3.82)	(3.32)	(17.22)	(15.67)
b)	Diluted	(2.12)	(2.40)	(2.09)	(10.82)	(9.85)
18.ii	Earnings Per Equity Share (EPS) (after extraordinary items) (F.V. of Re. 1/- each) (not annualised)					
a)	Basic	(3.37)	(3.82)	(3.32)	(17.22)	(16.82)
b)	Diluted	(2.12)	(2.40)	(2.09)	(10.82)	(10.57)
19	Debt Equity Ratio	N.A.	N.A.	N.A.	2.12	1.94
20	Debt Service Coverage Ratio (DSCR)	N.A.	N.A.	N.A.	0.05	0.07
21	Interest Service Coverage Ratio (ISCR)	N.A.	N.A.	N.A.	0.17	0.18

Paid-up Debt Capital represents Foreign Currency Convertible Bonds (FCCB)



STERLING BIOTECH LIMITED
 Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021
 CIN - L51900MH1985PLC035738

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Rs. In Lacs)

Sr. No.	Particulars	STANDALONE	
		Fifteen Months	Twelve Months
		31/03/2016	31/12/2014
		Audited	Audited
A	EQUITY AND LIABILITIES		
1	SHAREHOLDERS' FUND		
	a) Share Capital	186,966.70	153,403.14
	b) Reserves and Surplus	54,228.78	101,026.03
	c) Money received against share warrants	0.00	0.00
	Sub - total Shareholders' Funds	241,195.48	254,429.17
2	Share Application money pending allotment (Preference Shares)	1,158.50	0.00
3	Non-current liabilities		
	a) Long-term borrowings	231,203.83	186,114.64
	b) Deferred tax liabilities (net)	0.00	0.00
	c) Other long-term liabilities	0.00	0.00
	d) Long-term provisions	0.00	0.00
	Sub-total - Non-current liabilities	231,203.83	186,114.64
4	Current liabilities		
	a) Short-term borrowings	100,916.68	118,171.45
	b) Trade payables	2,233.49	2,469.06
	c) Other current liabilities	149,890.34	160,069.08
	d) Short-term provisions	0.00	0.00
	Sub-total - Current liabilities	253,040.51	280,709.59
	TOTAL - EQUITY AND LIABILITIES	726,598.32	721,253.40
B	ASSETS		
1	Non-current assets		
	a) Fixed assets	540,811.87	554,396.88
	b) Goodwill on consolidation	0.00	0.00
	c) Non-current investments	16,897.72	16,890.75
	d) Deferred tax assets (net)	47,547.99	25,036.99
	e) Long-term loans and advances	0.00	0.00
	f) Other non-current assets	16,238.03	18,857.07
	Sub-total - Non-current assets	621,495.61	615,181.69
2	Current assets		
	a) Current investments	0.00	0.00
	b) Inventories	71,753.03	63,456.54
	c) Trade receivables	4,225.27	18,055.92
	d) Cash and cash equivalents	1,663.88	1,765.92
	e) Short-term loans and advances	27,460.53	22,793.33
	f) Other current assets	0.00	0.00
	Sub-total - Current assets	105,102.71	106,071.71
	TOTAL - ASSETS	726,598.32	721,253.40



STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021
CIN - L51900MH1985PLC035738

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and approved by the Board of Directors in its meeting held on 30 May 2016 and have been Audited by the Statutory Auditors of the Company.
- 3 The Company has Overseas Subsidiary and there are no business operations in the subsidiary company.
- 4 During the Quarter the Company has issued 122.400 Equity Shares of Re. 1/- each pursuant to conversion of FCCBs.
- 5 The Figures of the last Quarter ended on 31 March 2016 are the Balancing figures between the audited figures in respect of the full financial year of 15 Months ended on 31 March 2016 and published year to date figures upto the fourth quarter ended on 31 December 2015 of the Current year.
- 6 The Company has, during the year of 15 months allotted 335,623,402 Unlisted 8% Redeemable Cumulative Non-Participating Non-Convertible Preference Shares carrying no Voting Rights of face value of Rs.10/- each at par.
- 7 The Secured, Redeemable, Non Convertible Debentures (NCD) issued by the Company have fully matured in the year 2015 and the Company has not made the repayment of the redemption amount and interest thereon.
- 8 The Board has not recommended any dividend for the financial year ended 31 March 2016.
- 9 Previous period figures have been regrouped/reclassified, wherever necessary.

Place : Mumbai
Date : 30 May 2016.



For and on Behalf of
STERLING BIOTECH LIMITED


Chetan J. Sandesara
Joint Managing Director
(DIN:00255671)



INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF STERLING BIOTECH LIMITED

Report on the Financial Results

I have audited the financial results of Sterling Biotech Limited ("the Company"), for the financial year of 15 months ended on March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and / or 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the quarter ended March 31, 2016 as reported in the accompanying financial results are the derived figures between the audited figures in respect of the current full financial year of 15 months ended on March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the fourth quarter of the current financial year of 15 months. Further, the figures up to the end of the fourth quarter of the current year and the corresponding quarter for the previous year have only been reviewed by me and have not been subject to audit.

Management's Responsibility for the Financial Results

These financial results have been prepared on the basis of the audited financial statements of the Company for the year ended on March 31, 2016 and reviewed quarterly financial results up to December 31, 2015, being the date of the end of the fourth quarter of the current financial year of 15 months. Management is responsible for the preparation of these financial results that give a true and fair view of the net loss and other financial information in accordance with the recognition and measurement principles set out in the Accounting Standards referred to in the Companies Act, ("the Act") and other accounting principles generally accepted in India. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

My responsibility is to express an opinion on these financial results based on my audit of the financial results for the year of 15 months ended on March 31, 2016. I have conducted my audit in accordance with the auditing standards generally accepted in India. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. I believe that my audit provides a reasonable basis for my opinion.

Opinion

In my opinion and to the best of my information and according to the explanations given to me, the accompanying financial results:


- (a) are presented in accordance with the requirements of Regulation 33 and / or 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
- (b) give a true and fair view of the net loss and other financial results for the Quarter ended on March 31, 2016 and for the year of 15 months ended on March 31, 2016.

Further, as mentioned above, I report that the figures for the quarter ended March 31, 2016 as reported in the accompanying financial results are the derived figures between the audited figures in respect of the current full financial year of 15 months ended on March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the fourth quarter of the current financial year of 15 months, which were subjected to a limited review as mentioned above, as required under Regulation 33 and / or 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For H. S. HATHI & CO.

FIRM REG NO. 103593

CHARTERED ACCOUNTANTS



HEMANT S.HATHI

MEMBERSHIP NO. 37109

PROPRIETOR

DATE : 27th May 2016

PLACE : MUMBAI



STERLING BIOTECH LIMITED

CIN No. L51900MH1985PLC035738





Regd. Office. : 43 Atlanta Building, Nariman Point, Mumbai-400 021.
Tel. : +91(22) 6630 6732, 6630 6733 * Fax : +91 (22) 2204 1954

30 May 2016

FORM B

(for Audit Report with modified opinion)

For the Year of 15 months ended 31st March, 2016

1.	Name of the Company:	STERLING BIOTECH LIMITED
2.	Annual financial statements for the year ended	31 st March, 2016
3.	Type of Audit qualification	Qualified for default in repayment of the dues to Banks or financial institutions, etc.
4.	Frequency of qualification	The said Qualification appeared in Audit Report for the financial year ended 31.12.2011, 31.12.2012, 31.12.2013 and 31.12.2014.
5.	Draw attention to relevant notes in the annual financial statements and management response to the qualification in the directors' report:	The Company is in continuation dialogue with the lender for bilateral restructuring of its debt. Certain banks have already refinanced its debt.
6.	Additional comments from the board/audit committee chair:	The Company has been sanctioned Refinancing by most of the Banks and Company has substantially paid the over dues.
7.	To be signed by-	
	• CEO/Managing Director – Nitin Sandesara	
	• CFO – Nitin Sandesara	
	• Auditor of the company- H.S. Hathi & Co. Hemant S. Hathi, Proprietor	
	• Audit Committee Chairman – R. B. Dixit	

Corp. Office : Sandesara Estate, Atladra, Padra Road, Vadodara - 390 012.

Tel. : +91-265-2680720, 2680730 * Fax : +91-265-2680257, 2680732 * Email : sterling_gelatin@stergel.com

Works : ECP Road, Village Karakhadi - 391 450. Ta : Padra, Dist. : Vadodara, Gujarat, India. Tel. : (02662) 273292/94, 273364/65/67 * Fax : (02662) 273293